Evaluation of BEMA® Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects

NCT ID: NCT01713803

Last Updated: 2017-05-04

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE3
• Study Classification: INTERVENTIONAL
• Study Completion Date: 2017-05-01

Brief Summary

This is a randomized, double blind, placebo controlled study in opioid dependent subjects. Subjects meeting entry criteria will be treated with multiple doses of B-BNX or B-Placebo, with non-responders rescued within 6 hours. Open treatment B-BNX will be administered as follow-up therapy. Clinical efficacy assessments include the clinical opioid withdrawal scale (COWS), subject-rated assessments, and a urine drug screen.

Conditions

Opioid Dependence

Study Groups

Sugar pill

Group Type: PLACEBO_COMPARATOR

Buprenorphine and naloxone

Intervention Type: DRUG

buprenorphine and nalaxone

Group Type: EXPERIMENTAL

Buprenorphine and naloxone

Intervention Type: DRUG

Interventions

Buprenorphine and naloxone

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Signed informed consent obtained prior to any study procedure being performed
• Subject is a male or non-lactating female with a negative urine pregnancy test
• Subject is aged 18 to 65 years, inclusive
• Current diagnosis of opioid dependence or addiction per the Diagnostic and Statistical Manual of Mental Disorders - 4th edition (text revision) (DSM-IV-TR) criteria including physical dependence on opioids
• Daily short-acting opiate use of at least 60 mg morphine equivalent no opioid use for at least 12 hours prior to Screening with positive opiate result on urine drug screen
• Clinical opioid withdrawal scale (COWS) score ≥9
• Subject is in good general health in the judgment of the Investigator as determined from the physical and oral examination findings.

Exclusion Criteria

• Use of a long-acting opioid within the last 72 hours
• Use of an investigational drug or device within the last 30 days
• History of hypersensitivity, allergy, or intolerance to buprenorphine, naloxone, or related drugs
• Immediate suicidal risk, as determined by meeting any of the following:

1. History of suicidal ideation ≤ 3 months prior to Baseline with a score of 4 (intent to act) or 5 (specific plan and intent) on the eC-SSRS

2. History of suicidal behavior ≤1 year prior to Baseline (actual attempt, interrupted attempt, aborted attempt and/or preparatory acts/behavior) on the eC-SSRS

• A history or current evidence of any clinically significant disorder or any other condition which in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

BioDelivery Sciences International

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Birmingham, Alabama, United States

Countries

United States

Other Identifiers

BNX-350

Identifier Type: -

Identifier Source: org_study_id